primari
biolog
action
secosteroid
hormon
vitamin
oh
bind
vitamin
receptor
regul
serum
calcium
level
downstream
consequ
action
receptor
control
bone
format
mainten
first
clinic
manifest
insuffici
vdr
endocrin
signal
ricket
discov
daniel
whistler
netherland
centuri
year
later
vdr
gene
clone
bert
malley
date
research
vitamin
forefront
area
public
health
chemistri
biochemistri
includ
light
catalyz
synthesi
vitamin
adolf
windau
work
receiv
nobel
prize
chemistri
work
led
analys
vitamin
endocrin
metabol
led
remark
stride
describ
biochem
synthesi
oh
divers
biolog
vdr
particip
precursor
oh
cholecalciferol
vitamin
produc
skin
convert
liver
oh
circul
level
oh
serv
use
index
vitamin
total
bodi
store
hydroxyl
occur
princip
kidney
carbon
posit
encod
produc
biolog
activ
hormon
oh
second
mitochondri
cytochrom
enzym
encod
use
oh
oh
substrat
first
step
inactiv
pathway
metabolit
direct
role
oh
play
control
serum
calcium
level
elev
level
oh
block
synthesi
induc
inactiv
acceler
via
induct
classic
neg
feedback
loop
parallel
vdrcenter
discoveri
greater
awar
emerg
member
nuclear
hormon
receptor
nr
superfamili
vdr
member
result
vdr
nr
repres
wellstudi
human
transcript
factor
yield
signific
insight
mechan
transcript
control
worth
stress
fundament
import
precis
monitor
regul
serum
calcium
level
human
health
henc
endocrin
role
vdr
regul
calcium
homeostasi
critic
level
vitamin
depend
cutan
synthesi
initi
solar
radiat
dietari
intak
decreas
either
one
sourc
lead
insuffici
contribut
ultraviolet
light
uv
initi
cutan
convers
vitamin
greater
contribut
toward
final
oh
synthesi
vitamin
individu
import
relationship
solar
exposur
abil
captur
uvmedi
energi
underscor
invers
correl
human
skin
pigment
latitud
associ
oh
level
skin
pigment
lost
human
migrat
africa
adjust
life
reduc
solar
uv
exposur
result
individu
capac
gener
vitamin
respons
solar
uv
exposur
intim
associ
forebear
environment
adapt
correct
suffici
level
solar
exposur
serum
vitamin
matter
consider
debat
institut
medicin
recommend
daili
vitamin
intak
level
iud
group
popul
iud
year
age
howev
recommend
without
controversi
parallel
reassess
vitamin
impact
prevent
osteoporosi
suggest
correct
level
may
high
iud
may
reflect
accur
ancestr
serum
anoth
challeng
determin
given
intak
relat
serum
level
among
appropri
biochem
readout
measur
system
respons
howev
given
concert
research
focu
vdr
signal
exist
fairli
sophist
appreci
process
extens
first
report
vdr
action
could
control
cancer
cell
growth
discov
partli
serendip
partli
logic
extens
studi
report
identifi
purifi
cell
fraction
bound
oh
high
encourag
investig
begin
consid
molecular
action
vdr
classic
tissu
involv
calcium
homeostasi
exampl
skin
bone
intestin
kay
colston
first
demonstr
oh
nanomolar
concentr
inhibit
human
melanoma
cell
prolifer
vitro
worker
use
cancer
cell
model
serendipit
cancer
cell
model
readili
avail
studi
cell
cultur
experi
nonmalign
counterpart
cell
chosen
avail
adjac
laboratori
parallel
also
known
retinoid
also
small
lipophil
molecul
target
nr
could
drive
cell
differenti
exampl
leukemia
cell
line
turn
studi
led
pharmacolog
exploit
alltran
retino
acid
acut
promyelocyt
leukemia
apl
molecular
caus
apl
transloc
receptor
form
chimer
protein
chimer
protein
disrupt
control
differenti
give
rise
pharmacolog
dose
alltran
retino
acid
abl
trigger
differenti
therefor
therapi
apl
dramat
exampl
target
cancer
therapi
addit
find
contribut
significantli
rise
concept
differenti
alltran
retino
acid
remain
mainstay
therapi
major
catalyst
studi
rar
across
result
worker
began
consid
exploit
antiprolif
action
oh
differenti
therapi
cancer
first
instanc
abil
oh
induc
differenti
cultur
mous
human
myeloid
leukemia
cell
earli
onward
antiprolif
effect
oh
explor
wide
varieti
cancer
cell
line
includ
major
solid
tumor
cancer
cell
sustain
prolif
signal
silenc
cue
program
cell
death
signal
via
oh
drive
antiprolif
event
counter
insensit
antigrowth
signal
evas
apoptosi
cancer
cell
multipl
investig
examin
mechanist
basi
cell
sensit
vdr
antiprolif
respons
exampl
earli
studi
focus
understand
antiprolif
pathway
mediat
cell
cycl
program
cell
howev
studi
support
role
oh
block
imped
program
cell
histor
hematolog
malign
combin
eas
interrog
robust
classif
cellular
differenti
capac
envi
investig
solid
tumor
therefor
coincid
cell
system
led
identif
vdr
control
gene
control
cell
cycl
progress
includ
well
direct
bind
site
gene
encod
regul
seem
mechanist
enigmat
exemplifi
broad
effect
vdr
signal
transcript
translat
regul
enhanc
mrna
translat
attenu
degrad
mechan
describ
upregul
princip
mediat
cell
cycl
arrest
oh
shown
mediat
cell
cycl
arrest
number
cancer
cell
line
via
direct
induct
concomit
event
downregul
cyclin
cyclin
decreas
kinas
activ
associ
activ
complex
ultim
dephosphoryl
retinoblastoma
protein
sequestr
famili
member
repress
concomit
chang
cell
cycl
oh
induc
differenti
clearli
evid
myeloid
cell
line
also
support
cell
type
like
reflect
intim
link
exist
regul
transit
induct
cellular
program
cell
death
report
breast
cancer
model
leukemia
evid
level
famili
protein
tightli
treatment
oh
upregul
vitamin
upregul
protein
bind
disulfid
reduc
protein
thioredoxin
inhibit
abil
neutral
reactiv
oxygen
speci
turn
lead
stressinduc
vdr
signal
enhanc
adhes
suppress
invas
capac
cell
mani
effect
associ
differenti
phenotyp
eleg
seri
studi
munoz
cowork
dissect
relationship
vdr
signal
invas
colon
cancer
cell
line
primari
worker
establish
delic
interplay
vdr
ecadherin
wnt
signal
pathway
cell
line
clinic
sampl
other
examin
adhes
protein
express
cancer
model
suggest
mechan
may
generaliz
beyond
colon
cancer
essenti
compon
cancer
abil
replic
without
limit
often
requir
silenc
mechan
genom
surveil
vdr
seem
play
role
maintain
genom
integr
facilit
dna
repair
close
cooper
vdr
action
tumor
suppressor
pathway
correl
data
suggest
gener
cell
respond
oh
profoundli
wildtyp
molecular
level
sever
target
gene
share
signal
pathway
notabl
skin
vdr
signal
combin
surveil
genom
damag
regul
mitosi
epitheli
tissu
close
cooper
vdr
regul
mrna
protein
via
transcript
activ
support
role
genom
identifi
critic
target
gene
mediat
action
comprehens
genomewid
transcriptom
screen
reveal
broad
consensu
certain
target
also
highlight
signific
histori
vdrcentric
transcriptom
studi
support
cell
phenotyp
exampl
studi
isogen
cell
pair
differ
sensit
oh
signal
identifi
network
mediat
antiprolif
sensit
manner
signific
role
crosstalk
vdr
transform
growth
factor
tgf
signal
addit
similar
studi
shown
vdr
transcript
target
distinguish
leukemia
list
gene
target
common
across
cell
model
seem
short
clearli
share
target
beyond
commonli
enrich
gene
network
often
focu
cell
cycl
control
signal
transduct
howev
substanti
variat
experiment
design
eg
dose
exposur
time
use
oh
analog
limit
strict
comparison
thu
although
formal
metaanalysi
reveal
common
theme
seem
clear
littl
overlap
transcriptom
studi
also
noteworthi
dataset
develop
aim
noncod
rna
therefor
divers
vdr
regul
transcriptom
like
increas
recent
transcriptom
studi
complement
vdr
chipseq
studi
vdr
genom
bind
pattern
captur
vdr
chipseq
studi
perform
sever
human
cell
presenc
andor
absenc
ligand
reveal
impact
ligand
bind
vdr
genom
target
arguabl
vdr
chipseq
studi
import
transcriptom
studi
reveal
direct
vdr
genom
interact
wherea
transcriptom
analys
inevit
includ
direct
indirect
vdrmediat
effect
vdr
chipseq
analysi
reveal
approxim
genom
loci
normal
distribut
around
transcript
start
site
reflect
binomi
distribut
found
transcript
mani
loci
found
consider
distanc
transcript
start
site
anoth
import
find
studi
dual
hexamer
dna
motif
space
bp
socal
found
major
promin
genom
vdr
bind
site
bind
motif
also
suggest
exampl
invert
palindrom
space
bp
socal
applic
chipseq
approach
nr
gener
reveal
greater
bind
site
divers
previous
expect
addit
import
flank
region
cofactor
biolog
import
determin
aspect
transcript
regul
describ
greater
depth
j
wesley
pike
sylvia
christako
articl
biolog
mechan
action
vitamin
hormon
issu
precis
frequenc
type
element
part
remain
ambigu
depend
number
variabl
includ
depth
sequenc
read
precis
discoveri
motif
algorithm
appli
statist
threshold
use
regardless
actual
percentag
vdr
bind
site
contain
motif
clear
vdr
bind
signific
level
genom
region
contain
canon
may
explain
vdr
interact
genom
direct
indirect
mode
review
compel
case
made
reanalysi
vdr
chipseq
data
genom
align
differenti
peak
call
rational
reanalys
twopart
analys
chipseq
trivial
term
statist
assumpt
exist
studi
analyz
differ
manner
therefor
possibl
threshold
cutoff
differ
studi
second
methodolog
chipseq
process
area
activ
develop
advanc
recent
approach
display
number
benefit
earlier
analyt
given
wealth
understand
broad
anticanc
action
vdr
aim
exploit
understand
cancer
set
use
rodent
model
major
intermediari
step
clinic
exploit
vdr
signal
either
chemoprevent
chemotherapi
set
clear
difficulti
investig
efficaci
target
vdr
either
oh
analogu
attract
pharmacolog
mice
human
spectra
ageassoci
malign
differ
human
key
metabol
differ
exist
recapitul
lifetim
effect
compound
need
establish
window
chemoprevent
effect
may
play
role
either
tumor
initi
progress
notwithstand
caveat
anim
extrem
use
tool
elucid
clearli
role
vdr
act
cancer
prevent
seri
anim
gener
vdrablat
background
cross
anim
tumor
disposit
phenotyp
first
instanc
evid
delet
reduc
vdr
level
alter
morpholog
furthermor
cross
vdrdefici
heterozygot
mice
mous
mammari
tumor
transgen
mice
gener
anim
show
degre
vdr
mammari
tumor
burden
cross
mice
reduc
presenc
one
wildtyp
vdr
allel
wildtyp
vdr
allel
altern
anim
demonstr
greater
suscept
carcinogen
challeng
exampl
challeng
mice
dmba
induc
preneoplast
lesion
mammari
gland
wildtyp
previous
worker
establish
delet
adenomat
polyposi
coli
apc
gene
mous
faith
recapitul
human
colon
cancer
turn
mice
exploit
examin
impact
vdr
delet
progress
colon
similar
studi
support
antitumorogen
role
vdr
numer
studi
examin
abil
dietari
pharmacolog
addit
vitamin
compound
either
prevent
tumor
format
inhibit
growth
xenograft
one
area
investig
impact
experiment
dietari
variat
impact
tumor
predisposit
longterm
studi
mice
fed
westernstyl
diet
eg
high
fat
phosphat
low
vitamin
calcium
content
exploit
examin
impact
vitamin
colon
cancer
similarli
vitamin
calcium
dietari
intervent
modul
colon
crypt
provid
rational
diet
inflamm
premalign
cell
could
interact
modul
cancer
epidemiolog
studi
cedric
garland
cowork
first
investig
relationship
intens
sunlight
exposur
cancer
incid
reveal
invers
correl
risk
colon
cancer
subsequ
extend
find
implic
relationship
exampl
level
major
circul
metabolit
vitamin
significantli
lower
breast
cancer
patient
agematch
howev
relationship
clearli
complex
reflect
lifetim
exposur
inde
control
lifestyl
factor
significantli
impact
strength
although
associ
studi
therefor
function
readili
infer
suggest
find
low
serum
level
unfavor
prognost
may
trigger
wors
chemotherapi
cancer
prostat
exampl
relationship
equivoc
posit
although
gener
result
abl
support
cancerprev
impact
vitamin
address
ambigu
investig
first
stage
random
supplement
one
vital
vitamin
trial
accru
peopl
examin
impact
supplement
vitamin
omega
fatti
acid
rang
patholog
princip
cancer
heart
diseas
collect
preclin
studi
aspect
epidemiolog
find
encourag
academ
pharmaceut
partnership
design
vitamin
analogu
may
optim
balanc
vivo
properti
use
chemoprevent
chemotherapi
agent
optim
vitamin
compound
vivo
anticanc
efficaci
aim
ensur
favor
balanc
calcium
mobil
action
result
hypercalcemia
enhanc
anticanc
action
target
vdr
sever
medicin
chemistri
group
undertook
goal
led
mani
way
group
milan
uskokov
hoffman
la
alongsid
lisa
binderup
leo
well
group
academ
set
includ
gari
togeth
investig
synthes
blizzard
vitamin
analogu
mani
promis
properti
resist
metabol
yet
toler
impact
serum
calcium
level
sever
analogu
serv
lead
compound
search
diseas
set
anticanc
action
vitamin
compound
exploit
exampl
phase
trial
undertaken
rang
advanc
led
target
phase
ii
trial
breast
case
regimen
welltoler
clinic
respons
time
modest
howev
part
may
reflect
dose
chosen
conserv
correct
endpoint
trial
would
measur
cellular
differenti
reduc
prolifer
enhanc
apoptosi
readili
undertaken
context
clinic
trial
challeng
illustr
consid
prostat
cancer
detail
number
investig
consid
option
treat
men
local
diseas
surgeri
studi
prostat
tumor
surgeri
character
known
vdr
target
gene
trial
nearli
patient
local
prostat
cancer
beer
administ
either
oh
placebo
week
radic
prostatectomi
express
chang
vdr
known
candid
vdr
target
gene
marker
cell
prolifer
examin
interestingli
vdr
downregul
treatment
group
wherea
gene
chosen
eg
unchang
other
replic
approach
doxercalciferol
reveal
signific
modul
interestingli
microarray
studi
oh
sensit
isogen
breast
cancer
cell
line
establish
critic
mediat
marker
sensit
toward
oh
investig
examin
question
efficaci
escal
dose
assess
well
higher
level
oh
togeth
studi
suggest
oh
given
prostat
cancer
patient
quit
high
dose
chang
express
vdrdepend
gene
observ
find
also
led
other
consid
chemotherapi
oh
could
potenti
combin
cytotox
agent
ad
clinic
benefit
combin
studi
intrins
challeng
vitamin
arena
novocea
undertook
approach
develop
new
formul
oh
cancer
therapi
combin
docetaxel
men
advanc
prostat
cancer
fail
hormon
therapi
socal
castrat
resist
prostat
cancer
base
numer
preclin
studi
singl
institut
clinic
studi
novocea
conduct
random
phase
iii
studi
ascent
aipc
studi
calcitriol
enhanc
taxoter
determin
whether
prostatespecif
antigen
respons
rate
defin
declin
prostatespecif
antigen
month
differ
standard
therapi
castrat
resist
prostat
cancer
time
docetaxel
weekli
intraven
week
everi
week
compar
dose
schedul
docetaxel
plu
mg
although
studi
meet
prostatespecif
antigen
respons
criteria
alter
overal
surviv
therefor
justifi
larg
random
trial
assess
surviv
new
trial
ascent
ii
halt
full
recruit
surviv
arm
reduc
compar
standard
care
howev
ascent
ii
trial
design
serious
flaw
chemotherapi
arm
equal
efficaci
design
trial
docetaxel
versu
docetaxel
b
placebo
substanti
data
exist
time
trial
initi
docetaxel
clearli
inferior
docetaxel
b
term
surviv
men
castrat
resist
prostat
cancer
therefor
trial
actual
design
ask
question
overcom
inferior
docetaxel
regimen
fundament
flaw
trial
dose
oh
chosen
neither
biolog
optim
maximum
toler
dose
studi
clearli
shown
time
higher
dose
calcitriol
given
safe
patient
howev
result
ascent
ii
interpret
calcitriol
potenti
docetaxel
henc
chemotherapi
larg
clinic
trial
conclus
base
adequ
data
result
applic
vitamin
formul
probabl
left
challeng
develop
given
tantal
preclin
epidemiolog
find
question
clinic
trial
success
clear
clinic
exploit
drug
hard
high
attrit
rate
drug
pass
preclin
develop
clinic
mani
therapi
struggl
balanc
preclin
promis
clinic
realiti
clinic
develop
pipelin
often
challeng
ensur
optim
clinic
trial
design
illustr
parp
inhibitor
antiangiogenesi
although
approv
us
food
drug
administr
requir
reanalys
defin
optim
therefor
possibl
vitamin
chemotherapi
fall
similar
fate
may
well
date
incomplet
understand
desir
anticanc
action
inappropri
clinic
trial
design
imped
clinic
success
vitamin
compound
major
focu
emerg
dissect
cancer
cell
vari
respons
oh
one
initi
focu
genet
variat
region
vdr
gene
exampl
start
codon
polymorph
exon
ii
end
gene
determin
use
foki
restrict
enzym
result
truncat
find
initi
suggest
function
relationship
vdr
gene
genet
variat
cancer
risk
larger
studi
associ
seem
equivoc
inde
also
reflect
fact
nation
human
genom
research
institut
genomewid
associ
studi
gwa
catalog
list
genomewid
signific
genet
variat
annot
vdr
relat
cancer
phenotyp
rather
genet
variat
vdr
seem
associ
immun
diabet
reproduct
also
genet
level
variou
investig
consid
cell
respons
oh
may
determin
express
activ
metabol
enzym
exampl
compar
genom
hybrid
studi
found
amplifi
human
breast
cancer
relat
pair
normal
other
reveal
reduc
mrna
protein
level
wide
varieti
cancer
cell
line
primari
togeth
find
suggest
cancer
cell
sensit
toward
oh
may
primarili
depend
autocrin
metabol
target
cell
rather
endocrin
synthesi
uptak
target
cell
rais
possibl
local
control
enzym
could
exploit
target
vdrcentric
therapi
final
other
consid
epigenet
mechan
may
disrupt
vdr
signal
evid
approach
aris
observ
oh
cell
still
often
respond
transcript
lack
transcript
respons
antiprolif
target
gene
sustain
even
enhanc
induct
data
suggest
vdr
transcriptom
skew
cancer
cell
disfavor
antiprolif
target
gene
lack
function
vdr
alon
explain
resist
interact
transcript
corepressor
examin
investig
turn
alter
interact
may
form
molecular
lesion
could
target
cotreat
oh
plu
hdac
biolog
clearli
genom
era
sum
total
gene
transcript
protein
metabolit
cell
captur
analyz
arguabl
achiev
human
genom
serv
major
catalyst
approach
research
consortia
appli
similar
technolog
approach
tackl
fundament
challeng
biolog
power
exampl
illustr
encyclopedia
dna
code
element
encod
roadmap
function
taxonom
analysi
intern
human
epigenom
cancer
genom
atla
tcga
genotypetissu
express
gtex
volum
data
gener
project
unpreced
truli
transform
term
question
address
manner
tackl
find
interpret
wide
translat
bioinformat
analys
central
gener
complex
dataset
investig
unbias
bioinformat
analys
reveal
organiz
insight
neither
obviou
intuit
unbias
agnost
analys
achiev
appli
algorithm
approach
depend
discret
mathemat
inform
theori
combin
graph
theori
data
mine
comput
scienc
gener
central
role
statist
scienc
manner
bioinformat
approach
offer
promis
reveal
underli
mechan
biolog
health
diseas
exampl
omic
technolog
appli
captur
genom
structur
variant
mutat
gene
protein
express
pattern
protein
posttransl
modif
metabolit
across
cell
state
bioinformat
analys
appli
step
data
captur
data
process
eg
filter
normal
establish
reproduc
chang
state
b
complex
integr
analys
combin
differ
omic
dataset
statist
scienc
central
step
ultim
goal
workflow
identifi
network
chang
state
final
identifi
node
exert
control
node
would
form
attract
target
interventionist
wet
laboratorybas
experi
sever
point
worth
stress
theoret
workflow
first
studi
design
phenotyp
definit
critic
second
analys
includ
denomin
eg
genom
detect
transcriptom
etc
chang
consid
appropri
backdrop
event
occur
cell
third
data
process
includ
normal
across
sampl
includ
replic
state
subsequ
filter
remov
larg
compon
signal
unchang
therefor
control
penalti
fals
discoveri
final
integr
step
high
potenti
creativ
novelti
volum
publicli
avail
data
grow
statist
approach
type
data
integr
occur
vari
repres
mani
key
biolog
question
futur
frame
mechan
vdr
signal
disrupt
cancer
therefor
analyz
paradigm
mine
analyz
larg
biolog
dataset
therefor
sever
bioinformat
approach
applic
vdr
first
instanc
appli
genom
denomin
allow
question
address
vdr
biolog
signific
exampl
cancer
signific
role
vdr
emerg
consid
genet
variat
gene
express
simplest
gtex
tcga
data
investig
identifi
normal
tissu
vdr
highli
express
cancer
commonli
alter
gtex
data
reveal
vdr
abund
tissu
colon
small
intestin
least
abund
basal
ganglia
brain
tissu
tcga
data
reveal
vdr
commonli
alter
delet
cohort
adenoid
cystic
carcinoma
interestingli
gtex
data
clearli
reflect
focu
preclin
epidemiolog
level
investig
vdr
colon
cancer
howev
studi
date
examin
vdr
context
adenoid
cystic
carcinoma
breast
cancer
data
deriv
differ
cancer
type
collect
approxim
patient
analys
data
subject
paper
date
strike
none
paper
identifi
genomewid
signific
role
disrupt
associ
vdr
tumor
phenotyp
comparison
tcga
paper
report
signific
relationship
often
biolog
signal
extrem
contextu
analys
cell
illustr
signific
role
vdr
act
distinct
transcript
unit
control
specif
point
cell
differenti
find
reveal
intric
mechanist
basi
earliest
cancer
studi
vdr
signal
reveal
exogen
vitamin
compound
trigger
cell
differenti
therefor
reflect
role
vdr
seem
play
myeloid
system
worth
stress
appar
import
vdr
immun
phenotyp
gwa
identifi
signific
role
vdr
genet
variat
immun
perhap
reflect
reproductionrel
function
vdr
murin
display
mammari
gland
phenotyp
genotyp
modul
cancer
incid
murin
cancer
howev
transcript
epigenom
control
breast
epitheli
system
human
cell
reveal
genomewid
signific
role
major
breast
cancer
paper
tcga
identifi
genomewid
signific
role
vdr
act
cancer
put
find
togeth
leukemia
common
cancer
suggest
vdr
act
direct
cancer
driver
either
loss
gain
function
find
may
limit
likelihood
therapeut
exploit
cancer
context
approach
appli
leverag
public
data
chang
denomin
possibl
address
question
center
around
vdr
relat
gene
therebi
limit
penalti
fals
discoveri
exampl
previous
analyz
transcript
factor
famili
implic
cancer
includ
nr
superfamili
across
tumor
differ
tumor
bootstrap
establish
across
cancer
nr
famili
significantli
downregul
neither
significantli
mutat
alter
copi
number
within
nr
found
sever
nr
uniqu
suppress
one
tumor
site
includ
vdr
colon
cancer
coad
cohort
find
may
reflect
strong
express
vdr
normal
colon
vdr
downregul
found
driven
copi
number
variat
mutat
thu
epigenet
mechan
may
primarili
respons
alter
wellestablish
literatur
support
link
corrupt
vdr
signal
colon
pancanc
analys
add
find
suggest
loss
vdrinduc
growth
restraint
may
appar
colon
cancer
cancer
alter
appar
vdr
chipseq
data
also
lend
combin
type
publicli
avail
data
ask
question
concern
vdr
function
exampl
attract
integr
approach
examin
signific
genet
variat
transcript
factor
bind
site
relat
phenotyp
diseas
suscept
test
possibl
genet
variat
impact
transcript
factor
function
underpin
trait
differ
diseas
phenotyp
analyt
challeng
given
size
dataset
potenti
fals
discoveri
variou
group
address
challeng
notabl
encod
roadmap
epigenom
consortia
leverag
remark
volum
chipseq
data
gener
merg
bind
site
gwa
data
reveal
rank
site
singl
nucleotid
polymorph
snp
seem
signific
impact
activ
multipl
transcript
howev
given
vdr
consid
consortia
recent
integr
vdr
nation
human
genom
research
institut
gwa
snp
snp
linkag
disequilibrium
provid
novel
insight
interact
diseas
phenotypeassoci
snp
vdr
bind
analys
appli
transcript
factor
motif
search
exploit
chipseq
data
identifi
signific
interact
vdr
transcript
factor
diseas
trait
manner
identifi
genet
variat
signific
genomewid
level
enrich
vdr
bind
site
share
nuclear
bind
region
relat
immun
phenotyp
includ
selfreport
howev
none
gwa
snp
identifi
vdr
bind
site
neither
type
motif
underscor
divers
vdr
bind
site
relat
cancer
phenotyp
howev
seem
signific
relationship
vdr
colon
cancer
given
vdr
highli
express
normal
colon
associ
control
local
nr
vdr
commonli
significantli
downregul
colon
cancer
test
possibl
leverag
vdr
chipseq
data
deriv
colon
cancer
express
vdr
target
gene
cluster
tumor
express
pattern
allow
test
relationship
express
vdr
target
gene
clinic
outcom
express
vdr
target
gene
either
significantli
repress
activ
coad
cohort
suggest
vdr
function
activ
repress
complex
basal
physiolog
activ
instanc
vdr
target
gene
specif
colon
cell
downregul
colon
cancer
act
tumor
quartil
express
pattern
significantli
associ
diseasefre
surviv
specif
patient
subgroup
opportun
avail
meaning
data
integr
chipseq
studi
judici
choic
cell
line
studi
exampl
tier
cell
line
encod
project
includ
cell
approxim
publicli
avail
genomewid
dataset
therefor
excit
opportun
vdr
chipseq
undertaken
one
model
term
integr
could
leverag
encod
roadmap
epigenom
data
enthusiasm
remain
exploit
vitamin
signal
cancer
system
partli
reflect
biolog
wellunderstood
toxic
associ
vitamin
compound
easili
monitor
manag
era
high
dimension
biolog
data
possibl
measur
dissect
action
vdr
signal
great
detail
seem
like
effort
continu
exploit
vitamin
compound
clinic
set
may
well
exploit
tool
accur
measur
tumor
type
burden
allow
vitamin
dcenter
therapi
appli
great
precis
seem
like
among
action
vdr
immunomodulatori
capac
may
ultim
one
advantag
cancer
therapi
